The MedTech M&A market has demonstrated remarkable resilience despite a period of macroeconomic uncertainty. However, the growth drivers of today look significantly different from those making waves during the pandemic era. A&M's Life Sciences team highlights trends, challenges, and strategies for the MedTech mergers and acquisitions (M&A) landscape, offering predictions for 2025 and beyond.
This report includes:
- Analysis of the shifting landscape of MedTech M&A in the post-pandemic era
- Strategic insights around how leading companies are leveraging M&A to drive competitive advantage
- Recommendations for both acquirers and targets
- Our predictions for M&A trends in the industry
Dive into the future of MedTech M&A and stay ahead of the curve in this rapidly evolving sector.
Download the Report
What if the biosimilar wave is just a ripple?
September 9, 2025
As biologics face a record-breaking patent cliff, the anticipated biosimilar wave may be more of a ripple than a wave. To thrive, life sciences firms must shift from solely pursuing speed to mastering precision.
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
